For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1242/Dermatological-Drugs-Market-Forecast-2014-2024
2. www.visiongain.com
Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.5 Glossary of Terms in this Report
2. Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 An Overview of Dermatology
2.2.1 The Structure of the Skin, Hair and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes and Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation of the Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
1. Executive Summary
2. Introduction to Dermatological Drugs
3. www.visiongain.com
Contents
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases of Clinical Trials
2.12 Dermatological Drugs in This Report
3. Dermatological Drugs: World Market 2014-2024
3.1 The World Dermatological Drugs Market in 2012 and 2013
3. Dermatological Drugs: World Market 2014-2024
4. www.visiongain.com
Contents
3.1.1 Leading Dermatological Drugs
3.1.2 Leading Companies in the Dermatological Drugs Market
3.2 World Dermatological Drugs Market: Sales Forecast 2014-2024
3.3 Psoriasis Drugs Lead the World Dermatological Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.5 World Dermatological Drugs Market: Drivers and Restraints 2014-2024
3.6 Opportunities for Blockbuster Sales
4. Leading National Markets 2014-2024
4.1 Geographical Breakdown of the World Dermatological Drugs Market
4.2 World Dermatological Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Dermatological Drugs Market 2014-2024
4.3.1 US Dermatological Drugs Market Forecast 2014-2024
4.3.2 US Dermatological Drugs Market: Trends and Developments
4.3.2.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2.2 A US Biosimilars Market?
4.4 Japanese Dermatological Drugs Market 2014-2024
4.4.1 Japanese Dermatological Drugs Market Forecast 2014-2024
4.4.2 Japanese Dermatological Drugs Market: Trends and Developments
4.4.2.1 The Cost of Treatment in Japan
4.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.5 Chinese Dermatological Drugs Market 2014-2024
4.5.1 Chinese Dermatological Drugs Market Forecast 2014-2024
4. Leading National Markets 2014-2024
5. www.visiongain.com
Contents
4.5.2 Chinese Dermatological Drugs Market: Trends and Developments
4.5.2.1 Expansion of Healthcare Coverage and Reimbursement
4.5.2.2 Rapid Advancement of Dermatology in China
4.5.2.3 Price Controls and the Anhui Model
4.6 EU5 Dermatological Drugs Market 2014-2024
4.6.1 German Dermatological Drugs Market Forecast 2014-2024
4.6.2 French Dermatological Drugs Market Forecast 2014-2024
4.6.3 UK Dermatological Drugs Market Forecast 2014-2024
4.6.4 Italian Dermatological Drugs Market Forecast 2014-2024
4.6.5 Spanish Dermatological Drugs Market Forecast 2014-2024
4.7 Indian Dermatological Drugs Market 2014-2024
4.7.1 Indian Dermatological Drugs Market Forecast 2014-2024
4.7.2 Indian Dermatological Drugs Market: Trends and Developments
4.7.2.1 Drug Prices Control Order 2013
4.7.2.2 Expansion of Healthcare Provision
4.8 Brazilian Dermatological Drugs Market 2014-2024
4.8.1 Brazilian Dermatological Drugs Market Forecast 2014-2024
4.8.2 Brazilian Dermatological Drugs Market: Trends and Developments
4.8.2.1 Increasing Access to Medicines
4.9 Russian Dermatological Drugs Market 2014-2024
4.9.1 Russian Dermatological Drugs Market Forecast 2014-2024
4.9.2 Russian Dermatological Drugs Market: Trends and Developments
4.9.2.1 Pharma2020, Healthcare and Industry Reform
4.10 Mexican Dermatological Drugs Market 2014-2024
6. www.visiongain.com
Contents
4.10.1 Mexican Dermatological Drugs Market Forecast 2014-2024
4.10.2 Mexican Dermatological Drugs Market: Trends and Developments
4.10.2.1 Seguro Popular: Mexican Healthcare Reform
4.10.2.2 International Interest in Mexico
5. Psoriasis Drugs Market 2014-2024
5.1 Drugs for Psoriasis: The Success of Biologics
5.2 Leading Products in the Psoriasis Drug Market in 2012 and 2013
5.3 Psoriasis Drugs: Trends and Developments
5.3.1 Biological Drugs: An Overview
5.3.1.1 Disadvantages of Biologics
5.4 Psoriasis Drugs: Market Forecast 2014-2024
5.5 Market Share of Leading Psoriasis Drugs to 2024
5.6 Humira (adalimumab, AbbVie)
5.6.1 Humira: Sales Forecast 2014-2024
5.6.2 Prospects for Biosimilar Humira
5.7 Enbrel (etanercept, Amgen/Pfizer)
5.7.1 Enbrel: Sales Forecast 2014-2024
5.7.2 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
5.7.3 Competition from Other Drugs
5.7.4 Biosimilar Competition for Enbrel
5.8 Stelara (ustekinumab, Johnson & Johnson)
5.8.1 Stelara: Sales Forecast 2014-2024
5.8.2 Competition for Stelara in the Pipeline
5. Psoriasis Drugs Market 2014-2024
7. www.visiongain.com
Contents
5.9 Remicade (infliximab, Johnson & Johnson)
5.9.1 Remicade: Sales Forecast 2014-2024
5.10 Daivobet (betamethasone/calcipotriene, LEO Pharma)
5.10.1 Daivobet: Sales Forecast 2014-2024
5.10.2 LEO Pharma’s Life Cycle Management of Daivobet
5.10.3 Daivobet/Dovobet/Taclonex – Generic Competition
5.11 Soriatane (acitretin, GSK)
5.11.1 Soriatane: Sales Forecast 2014-2024
5.12 Psoriasis Drugs Market: Summary
6. Skin Infection Drugs Market 2014-2024
6.1 Skin Infection Drugs: A Growing Submarket
6.2 Leading Products in the Skin Infections Drug Market in 2012 and 2013
6.3 Skin Infection Drugs: Market Forecast 2014-2024
6.4 Market Share of Leading Skin Infection Drugs to 2024
6.5 Cubicin (daptomycin, Cubist Pharmaceuticals)
6.5.1 Cubicin: Sales Forecast 2014-2024
6.5.2 Cubicin Lifecycle Management Strategies
6.5.3 Generic Competition for Cubicin
6.6 Zyvox (linezolid, Pfizer)
6.6.1 Zyvox: Sales Forecast 2014-2024
6.6.2 Tedizolid Threatens Zyvox Market Share
6.7 Valtrex (valaciclovir, GSK)
6.7.1 Valtrex: Sales Forecast 2014-2024
6. Skin Infection Drugs Market 2014-2024
8. www.visiongain.com
Contents
6.8 Canesten (clotrimazole, Bayer)
6.8.1 Canesten: Sales Forecast 2014-2024
6.9 Zovirax (aciclovir, Valeant/GSK)
6.9.1 Zovirax: Sales Forecast 2014-2024
6.9.2 Valeant Acquires Zovirax in US and Canada
6.9.3 Mylan’s Generic Zovirax and Actavis’s Authorised Generic
6.10 Bactroban (mupirocin, GSK)
6.10.1 Bactroban: Sales Forecast 2014-2024
6.11 Lamisil (terbinafine, Novartis)
6.11.1 Lamisil: Sales Forecast 2014-2024
6.11.2 Lamisil Sales Affected by Novartis Manufacturing Problems
6.12 Skin Infection Drugs Market: Summary
7. Acne Drugs Market 2014-2024
7.1 Drugs for Acne: A Highly Fragmented Market
7.2 Leading Products in the Acne Drug Market in 2012 and 2013
7.3 Acne Drugs: Trends and Developments
7.3.1 Combination Treatments for Acne
7.3.2 Oral Contraceptives in Treating Acne
7.3.3 Generic Competition in the Acne Drugs Market
7.4 Acne Drugs: Market Forecast 2014-2024
7.5 Market Share of Leading Acne Drugs to 2024
7.6 Solodyn (minocycline, Valeant)
7.6.1 Solodyn: Sales Forecast 2014-2024
7. Acne Drugs Market 2014-2024
16. www.visiongain.com
Contents
11. Qualitative Analysis of the Dermatological Drugs Market 2014-2024
11.1 SWOT Analysis of the Dermatological Drugs Market
11.2 Strengths
11.2.1 A Strong R&D Pipeline
11.2.2 High Unmet Clinical Need
11.2.3 Strong Industry-Physician Relationships
11.3 Weaknesses
11.3.1 Patient Adherence to Treatment
11.3.2 Limited Efficacy and Adverse Effects
11.3.3 Patent Expiry and Generic Competition
11.4 Opportunities
11.4.1 Growth Areas: Skin Infections, Onychomycosis and Melanoma
11.4.2 Consolidation in the Dermatology Market?
11.4.3 Personalised Dermatology: Technological Advances in Genomics
11.4.4 Advances in Topical Drug Delivery Methods
11.5 Threats
11.5.1 Increasing R&D Costs
11.5.2 Uncertain Reimbursement
11.5.3 Downward Pressures on Drug Prices
11.6 Porter’s Five Forces Analysis of the Dermatological Drugs Market
11.6.1 Rivalry Among Competitors [Medium]
11.6.2 Threat of New Entrants [High]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11. Qualitative Analysis of the Dermatological Drugs Market 2014-
17. www.visiongain.com
Contents
11.6.5 Threat of Substitutes [Medium]
12. Research Interviews
12.1 Interview with Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc.,
Knoxville, Tennessee, USA
12.1.1 Provectus’ Pipeline: PV-10 and PH-10
12.1.2 The Dermatological Drugs Market
12.2 Interview with Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern-
Öschelbronn, Germany
12.2.1 Birken’s Pipeline: Oleogel S-10
12.2.2 The Dermatological Drugs Market
12.3 Interview with Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake
Forest University School of Medicine, Winston-Salem, North Carolina, USA
12.3.1 Psoriasis: Unmet Patent Needs
12.3.2 Leading Dermatology Markets
12.3.3 Patient Adherence is Crucial
12.3.4 The Future of Biological Drug Treatments
12.3.5 Technological and Pipeline Developments
12.3.6 Challenges for Dermatologic Treatments
12.4 Interview with Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG,
Leverkusen, Germany
12.4.1 Current State of the Dermatological Drug Market
12.4.2 Biofrontera and Dermatologic Drugs
12.4.3 Future Prospects for the Dermatological Drug Market
12.4.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers
12. Research Interviews
18. www.visiongain.com
Contents
12.4.5 Challenges Facing the Dermatologic Drug Market
12.4.6 Thoughts on Biologics, Small Molecule and Combination Therapies
13. Conclusions
13.1 The World Dermatological Drugs Market in 2012 and 2013
13.1.1 Current Leading Dermatological Drugs Segments
13.1.2 Leading Dermatological Drugs Products
13.1.3 Leading Dermatological Drugs Companies
13.1.4 Leading National Markets
13.2 World Dermatological Drugs Market Forecast 2014-2024
13.3 The Future of the Dermatological Drugs Market?
13. Conclusions
19. www.visiongain.com Page 98
Dermatological Drugs Market Forecast 2014-2024:
Future Prospects for Leading Companies
Table 4.12 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2012-2024
2012 2013 2014 2015 2016 2017 2018
Spain ($m) 452 487 521 551 570 592 602
Annual Growth Rate (%) 7.9 7.1 5.6 3.5 3.9 1.6
CAGR (%, 2012-2018) 4.9
2018 2019 2020 2021 2022 2023 2024
Spain ($m) 602 617 633 647 666 682 695
Annual Growth Rate (%) 1.6 2.5 2.5 2.4 2.8 2.4 2.0
CAGR (%, 2018-2024) 2.4
CAGR (%, 2012-2024) 3.7
Figure 4.15 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%),
2012-2024
Visiongain predicts that the Spanish market will grow with a CAGR of 4.9% over 2012-2018 to
reach $602m in 2018. As in other EU countries, growth in healthcare spending will be limited by
slow economic growth. In 2011, a fall in total spending was noted by the Spanish health ministry.
The market will be restrained by recent financial problems and laws introduced by the Spanish
government mean that the pharmaceutical market will be increasingly supplied with generic drugs;
therefore making a challenging R&D environment over the forecast period. However, the need for
new dermatologic drug treatments, such as those for treating skin cancer and skin and skin
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
0
100
200
300
400
500
600
700
800
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales($m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014
20. www.visiongain.com Page 123
Dermatological Drugs Market Forecast 2014-2024:
Future Prospects for Leading Companies
The annual cost of treatment with Stelara is reportedly $18,200 for a low dose or $33,600 for a
high dose. This is apparently more expensive than $14,543 Enbrel and $16,978 Humira, reports
also indicate. The drug’s high revenue is affected by this high cost; in 2012, sales of Stelara
generated $1,025m.
5.8.1 Stelara: Sales Forecast 2014-2024
Table 5.7 and Figure 5.7 show visiongain’s estimates of Stelara revenues in psoriasis and psoriatic
arthritis over 2012-2024.
Table 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), CAGR (%), 2012-2024
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Stelara ($m) 1,025 1,504 1,835 2,055 2,240 2,419 2,540 2,667 2,774 2,829 2,914 2,943 1,913
Annual Growth Rate (%) 46.7 22.0 12.0 9.0 8.0 5.0 5.0 4.0 2.0 3.0 1.0 -35.0
CAGR (%, 2012-2018
and 2018-2024)
16.3 -4.6
CAGR (%, 2012-2024) 5.3
Figure 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), 2012-2024
In 2012, Johnson & Johnson reported Stelara revenues of $1,025m, representing 16.9% of the
psoriasis drugs market. This increased in 2013 to $1,504m, up 46.7% on 2012. Growth was due to
-40.0
-30.0
-20.0
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
0
500
1,000
1,500
2,000
2,500
3,000
3,500
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales($m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014
21. www.visiongain.com Page 200
Dermatological Drugs Market Forecast 2014-2024:
Future Prospects for Leading Companies
The company reports revenues from its Dermatology business segment, which includes Bactroban
and Duac (and presumably Soriatane) but excludes Valtrex and Zovirax. GSK also markets drugs
for treating melanoma, notably Tafinlar and Mekinist, though these have not been considered part
of GSK’s dermatology revenues.
9.4.2 GSK: Sales Forecast 2014-2024
Table 9.8 and Figure 9.4 show visiongain’s estimates of GSK’s dermatological drugs revenues
over 2012-2024.
Table 9.8 GSK: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
GSK ($m) 1,888 1,682 1,544 1,497 1,468 1,450 1,439 1,435 1,416 1,401 1,390 1,379 1,370
Annual Growth Rate (%) -10.9 -8.2 -3.0 -2.0 -1.2 -0.7 -0.3 -1.3 -1.0 -0.8 -0.7 -0.7
CAGR (%, 2012-2018
and 2018-2024)
-4.4 -0.8
CAGR (%, 2012-2024) -2.6
Figure 9.4 GSK: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Visiongain’s sales forecast for GSK includes GSK’s reported Dermatology revenues, as well as
sales of Valtrex and GSK’s share of sales of Zovirax. We estimate that in 2012, GSK's
-12.0
-10.0
-8.0
-6.0
-4.0
-2.0
0.0
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2,000
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales($m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014